Overall, studies suggested that in cancer, increased expression of NRP1 has been linked to a poor prognosis and low responsiveness and resistance to radiotherapy and chemotherapy in various cancer types through facilitating aberrant growth factor signaling during EMT-associated drug resistance and metastasis [42, 45]. The gene discussed is NRP1; the disease is cancer.